AI assistant
Sending…
PMV Pharmaceuticals, Inc. — Director's Dealing 2023
Jun 12, 2023
34350_dirs_2023-06-12_4c7423aa-e7fd-4aeb-8756-a4c394e0c2b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2023-06-08
Reporting Person: Heyman Richard A. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-08 | Stock Option (right to buy) | $5.59 | A | 21500 | Acquired | 2033-06-07 | Common Stock (21500) | Direct |
Footnotes
F1: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
More from PMV Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 9
Interim / Quarterly Report
2025
Nov 12
Regulatory Filings
2025
Nov 12
Major Shareholding Notification
2025
Nov 12
Director's Dealing
2025
Oct 29